Delta-Fly Pharma, Inc. (4598) Stock Statistics & Valuation Metrics

Delta-Fly Pharma, Inc. has a market cap or net worth of ¥2.71B. The enterprise value is ¥2.42B.

Delta-Fly Pharma, Inc. has 12,159,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Delta-Fly Pharma, Inc.’s return on equity (ROE) is -1.16 and return on invested capital (ROIC) is -113.86%.

The current PE Ratio of Delta-Fly Pharma, Inc. is ―. Delta-Fly Pharma, Inc.’s PEG ratio is 1.82.

In the last 12 months, Delta-Fly Pharma, Inc. had revenue of 0.00 and earned -1.43B in profits. Earnings per share was -198.80.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Delta-Fly Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Delta-Fly Pharma, Inc. upcoming earnings date is May 14, 2026, TBA (Confirmed).

Delta-Fly Pharma, Inc. as a current ratio of 5.93, with Debt / Equity ratio of ―

In the past 12 months, Delta-Fly Pharma, Inc. has paid 2.50M in taxes.

Delta-Fly Pharma, Inc. EV to EBITDA ratio is -2.08, with an EV/FCF ratio of -2.27.

Delta-Fly Pharma, Inc. has ¥738.00M in cash and marketable securities with ¥0.00 in debt, giving a net cash position of ¥738.00M billion.

Gross margin is ―, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Delta-Fly Pharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―